Successful treatment of paraganglioma with sorafenib: a case report and brief review of the literature
Yun Lin,1,* Qun Li,1,* Wei Huang,1 Xinyan Jia,1 Hong Jiang,1 Yong Gao,1 Qi Li1,21Department of Oncology, Shanghai East Hospital, 2Department of Oncology, Shanghai First People's Hospital, Shanghai, People's Republic of China*These authors contributed equally to this work, and are joi...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-11-01
|
Series: | OncoTargets and Therapy |
Online Access: | http://www.dovepress.com/successful-treatment-of-paraganglioma-with-sorafenib-a-case-report-and-a14883 |
id |
doaj-4b4fc69d4edd446887f5f27dacab59f4 |
---|---|
record_format |
Article |
spelling |
doaj-4b4fc69d4edd446887f5f27dacab59f42020-11-24T22:36:07ZengDove Medical PressOncoTargets and Therapy1178-69302013-11-012013default15591562Successful treatment of paraganglioma with sorafenib: a case report and brief review of the literatureLin YLi QHuang WJia XJiang HGao YLi QYun Lin,1,* Qun Li,1,* Wei Huang,1 Xinyan Jia,1 Hong Jiang,1 Yong Gao,1 Qi Li1,21Department of Oncology, Shanghai East Hospital, 2Department of Oncology, Shanghai First People's Hospital, Shanghai, People's Republic of China*These authors contributed equally to this work, and are joint first authorsIntroduction: To date, no effective systemic therapies have been made available for paraganglioma. However, multiple mutations in susceptibility genes have been identified that are potential targets for sorafenib, an oral multitargeted tyrosine-kinase inhibitor.Case presentation: We report the case of a 69-year-old Chinese man with mediastinal paraganglioma that had metastasized to the bone. The paraganglioma responded to sorafenib, a novel multi-tyrosine kinase inhibitor that targets angiogenesis, the Raf-kinase pathway, the platelet-derived growth factor Ret, and c-Kit. The patient was diagnosed as having paraganglioma after biopsy of the mediastinal mass. We first treated the patient with radiotherapy. Then he tolerated an etoposide-and-cisplatin chemotherapy regimen. Subsequently, he received 6 months of maintenance treatment with sorafenib (400 mg twice daily). A dramatic reduction in tumor volume was observed. At present, the patient has achieved a partial response, and his clinical status remains unchanged.Conclusion: We suggest that sorafenib should be further investigated in the management of patients with paraganglioma.Keywords: sorafenib, paraganglioma, molecular-targeted drughttp://www.dovepress.com/successful-treatment-of-paraganglioma-with-sorafenib-a-case-report-and-a14883 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lin Y Li Q Huang W Jia X Jiang H Gao Y Li Q |
spellingShingle |
Lin Y Li Q Huang W Jia X Jiang H Gao Y Li Q Successful treatment of paraganglioma with sorafenib: a case report and brief review of the literature OncoTargets and Therapy |
author_facet |
Lin Y Li Q Huang W Jia X Jiang H Gao Y Li Q |
author_sort |
Lin Y |
title |
Successful treatment of paraganglioma with sorafenib: a case report and brief review of the literature |
title_short |
Successful treatment of paraganglioma with sorafenib: a case report and brief review of the literature |
title_full |
Successful treatment of paraganglioma with sorafenib: a case report and brief review of the literature |
title_fullStr |
Successful treatment of paraganglioma with sorafenib: a case report and brief review of the literature |
title_full_unstemmed |
Successful treatment of paraganglioma with sorafenib: a case report and brief review of the literature |
title_sort |
successful treatment of paraganglioma with sorafenib: a case report and brief review of the literature |
publisher |
Dove Medical Press |
series |
OncoTargets and Therapy |
issn |
1178-6930 |
publishDate |
2013-11-01 |
description |
Yun Lin,1,* Qun Li,1,* Wei Huang,1 Xinyan Jia,1 Hong Jiang,1 Yong Gao,1 Qi Li1,21Department of Oncology, Shanghai East Hospital, 2Department of Oncology, Shanghai First People's Hospital, Shanghai, People's Republic of China*These authors contributed equally to this work, and are joint first authorsIntroduction: To date, no effective systemic therapies have been made available for paraganglioma. However, multiple mutations in susceptibility genes have been identified that are potential targets for sorafenib, an oral multitargeted tyrosine-kinase inhibitor.Case presentation: We report the case of a 69-year-old Chinese man with mediastinal paraganglioma that had metastasized to the bone. The paraganglioma responded to sorafenib, a novel multi-tyrosine kinase inhibitor that targets angiogenesis, the Raf-kinase pathway, the platelet-derived growth factor Ret, and c-Kit. The patient was diagnosed as having paraganglioma after biopsy of the mediastinal mass. We first treated the patient with radiotherapy. Then he tolerated an etoposide-and-cisplatin chemotherapy regimen. Subsequently, he received 6 months of maintenance treatment with sorafenib (400 mg twice daily). A dramatic reduction in tumor volume was observed. At present, the patient has achieved a partial response, and his clinical status remains unchanged.Conclusion: We suggest that sorafenib should be further investigated in the management of patients with paraganglioma.Keywords: sorafenib, paraganglioma, molecular-targeted drug |
url |
http://www.dovepress.com/successful-treatment-of-paraganglioma-with-sorafenib-a-case-report-and-a14883 |
work_keys_str_mv |
AT liny successfultreatmentofparagangliomawithsorafenibacasereportandbriefreviewoftheliterature AT liq successfultreatmentofparagangliomawithsorafenibacasereportandbriefreviewoftheliterature AT huangw successfultreatmentofparagangliomawithsorafenibacasereportandbriefreviewoftheliterature AT jiax successfultreatmentofparagangliomawithsorafenibacasereportandbriefreviewoftheliterature AT jiangh successfultreatmentofparagangliomawithsorafenibacasereportandbriefreviewoftheliterature AT gaoy successfultreatmentofparagangliomawithsorafenibacasereportandbriefreviewoftheliterature AT liq successfultreatmentofparagangliomawithsorafenibacasereportandbriefreviewoftheliterature |
_version_ |
1725721245936254976 |